Literature DB >> 19899162

Highly conserved glycine 86 and arginine 87 residues contribute differently to the structure and activity of the mature HIV-1 protease.

Rieko Ishima1, Qingguo Gong, Yunfeng Tie, Irene T Weber, John M Louis.   

Abstract

The structural and functional role of conserved residue G86 in HIV-1 protease (PR) was investigated by NMR and crystallographic analyses of substitution mutations of glycine to alanine and serine (PR(G86A) and PR(G86S)). While PR(G86S) had undetectable catalytic activity, PR(G86A) exhibited approximately 6000-fold lower catalytic activity than PR. (1)H-(15)N NMR correlation spectra revealed that PR(G86A) and PR(G86S) are dimeric, exhibiting dimer dissociation constants (K(d)) of approximately 0.5 and approximately 3.2 muM, respectively, which are significantly lower than that seen for PR with R87K mutation (K(d) > 1 mM). Thus, the G86 mutants, despite being partially dimeric under the assay conditions, are defective in catalyzing substrate hydrolysis. NMR spectra revealed no changes in the chemical shifts even in the presence of excess substrate, indicating very poor binding of the substrate. Both NMR chemical shift data and crystal structures of PR(G86A) and PR(G86S) in the presence of active-site inhibitors indicated high structural similarity to previously described PR/inhibitor complexes, except for specific perturbations within the active site loop and around the mutation site. The crystal structures in the presence of the inhibitor showed that the region around residue 86 was connected to the active site by a conserved network of hydrogen bonds, and the two regions moved further apart in the mutants. Overall, in contrast to the role of R87 in contributing significantly to the dimer stability of PR, G86 is likely to play an important role in maintaining the correct geometry of the active site loop in the PR dimer for substrate binding and hydrolysis. Proteins 2010. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19899162      PMCID: PMC2811763          DOI: 10.1002/prot.22625

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  39 in total

Review 1.  Retroviral proteinases.

Authors:  S Oroszlan; R B Luftig
Journal:  Curr Top Microbiol Immunol       Date:  1990       Impact factor: 4.291

2.  Mutational and structural studies aimed at characterizing the monomer of HIV-1 protease and its precursor.

Authors:  Rieko Ishima; Dennis A Torchia; John M Louis
Journal:  J Biol Chem       Date:  2007-04-04       Impact factor: 5.157

3.  Structural and evolutionary relationships between retroviral and eucaryotic aspartic proteinases.

Authors:  J K Rao; J W Erickson; A Wlodawer
Journal:  Biochemistry       Date:  1991-05-14       Impact factor: 3.162

4.  Effect of flap mutations on structure of HIV-1 protease and inhibition by saquinavir and darunavir.

Authors:  Fengling Liu; Andrey Y Kovalevsky; Yunfeng Tie; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2008-07-01       Impact factor: 5.469

Review 5.  Resistance to HIV protease inhibitors.

Authors:  J H Condra
Journal:  Haemophilia       Date:  1998-07       Impact factor: 4.287

6.  Database of three-dimensional structures of HIV proteinases.

Authors:  J Vondrasek; C P van Buskirk; A Wlodawer
Journal:  Nat Struct Biol       Date:  1997-01

7.  Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.

Authors:  I T Weber; J Wu; J Adomat; R W Harrison; A R Kimmel; E M Wondrak; J M Louis
Journal:  Eur J Biochem       Date:  1997-10-15

8.  NMRPipe: a multidimensional spectral processing system based on UNIX pipes.

Authors:  F Delaglio; S Grzesiek; G W Vuister; G Zhu; J Pfeifer; A Bax
Journal:  J Biomol NMR       Date:  1995-11       Impact factor: 2.835

9.  Rapid structural fluctuations of the free HIV protease flaps in solution: relationship to crystal structures and comparison with predictions of dynamics calculations.

Authors:  Darón I Freedberg; Rieko Ishima; Jaison Jacob; Yun-Xing Wang; Irina Kustanovich; John M Louis; Dennis A Torchia
Journal:  Protein Sci       Date:  2002-02       Impact factor: 6.725

10.  Solution structure of the mature HIV-1 protease monomer: insight into the tertiary fold and stability of a precursor.

Authors:  Rieko Ishima; Dennis A Torchia; Shannon M Lynch; Angela M Gronenborn; John M Louis
Journal:  J Biol Chem       Date:  2003-08-21       Impact factor: 5.157

View more
  11 in total

1.  Novel P2 tris-tetrahydrofuran group in antiviral compound 1 (GRL-0519) fills the S2 binding pocket of selected mutants of HIV-1 protease.

Authors:  Hongmei Zhang; Yuan-Fang Wang; Chen-Hsiang Shen; Johnson Agniswamy; Kalapala Venkateswara Rao; Chun-Xiao Xu; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2013-01-23       Impact factor: 7.446

2.  Hydration Structure and Dynamics of Inhibitor-Bound HIV-1 Protease.

Authors:  Florian Leidner; Nese Kurt Yilmaz; Janet Paulsen; Yves A Muller; Celia A Schiffer
Journal:  J Chem Theory Comput       Date:  2018-04-18       Impact factor: 6.006

3.  Can cyclic HIV protease inhibitors bind in a non-preferred form? An ab initio, DFT and MM-PB(GB)SA study.

Authors:  Daniel P Oehme; Robert T C Brownlee; David J D Wilson
Journal:  J Mol Model       Date:  2012-11-13       Impact factor: 1.810

4.  Understanding HIV-1 protease autoprocessing for novel therapeutic development.

Authors:  Liangqun Huang; Chaoping Chen
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

Review 5.  Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem.

Authors:  Ge-Fei Hao; Guang-Fu Yang; Chang-Guo Zhan
Journal:  Drug Discov Today       Date:  2012-07-10       Impact factor: 7.851

6.  Probing multidrug-resistance and protein-ligand interactions with oxatricyclic designed ligands in HIV-1 protease inhibitors.

Authors:  Arun K Ghosh; Chun-Xiao Xu; Kalapala Venkateswara Rao; Abigail Baldridge; Johnson Agniswamy; Yuan-Fang Wang; Irene T Weber; Manabu Aoki; Salcedo Gomez Pedro Miguel; Masayuki Amano; Hiroaki Mitsuya
Journal:  ChemMedChem       Date:  2010-11-08       Impact factor: 3.466

7.  Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation.

Authors:  Dan Li; Ying Zhang; Run-Ning Zhao; Song Fan; Ju-Guang Han
Journal:  J Mol Model       Date:  2014-02-14       Impact factor: 1.810

8.  Mutations Proximal to Sites of Autoproteolysis and the α-Helix That Co-evolve under Drug Pressure Modulate the Autoprocessing and Vitality of HIV-1 Protease.

Authors:  John M Louis; Lalit Deshmukh; Jane M Sayer; Annie Aniana; G Marius Clore
Journal:  Biochemistry       Date:  2015-08-21       Impact factor: 3.162

9.  Dimer Interface Organization is a Main Determinant of Intermonomeric Interactions and Correlates with Evolutionary Relationships of Retroviral and Retroviral-Like Ddi1 and Ddi2 Proteases.

Authors:  János András Mótyán; Márió Miczi; József Tőzsér
Journal:  Int J Mol Sci       Date:  2020-02-17       Impact factor: 5.923

10.  HIV-1 Nef inhibits Protease activity and its absence alters protein content of mature viral particles.

Authors:  Luiza M Mendonça; Sandro C Poeys; Celina M Abreu; Amilcar Tanuri; Luciana J Costa
Journal:  PLoS One       Date:  2014-04-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.